Paclitaxel is incorporated by mesenchymal stromal cells and released in exosomes that inhibit in vitro tumor growth: a new approach for drug delivery
- PMID: 25084218
- DOI: 10.1016/j.jconrel.2014.07.042
Paclitaxel is incorporated by mesenchymal stromal cells and released in exosomes that inhibit in vitro tumor growth: a new approach for drug delivery
Abstract
Mesenchymal stromal cells (MSCs) have been proposed for delivering anticancer agents because of their ability to home in on tumor microenvironment. We found that MSCs can acquire strong anti-tumor activity after priming with Paclitaxel (PTX) through their capacity to uptake and then release the drug. Because MSCs secrete a high amount of membrane microvesicles (MVs), we here investigated the role of MVs in the releasing mechanism of PTX. The murine SR4987 line was used as MSC model. The release of PTX from SR4987 in the conditioned medium (CM) was checked by HPLC and the anti-tumor activity of both CM and MVs was tested on the human pancreatic cell line CFPAC-1. MVs were isolated by ultracentrifugation, analyzed by transmission (TEM) and scanning electron microscopy (SEM), and the presence of PTX by the Fourier transformed infrared (FTIR) microspectroscopy. SR4987 loaded with PTX (SR4987PTX) secreted a significant amount of PTX and their CM possessed strong anti-proliferative activity on CFPAC-1. At TEM and SEM, SR4987PTX showed an increased number of "vacuole-like" structures and shed a relevant number of MVs, but did not differ from untreated SR4987. However, SR4987PTX-derived-MVs (SR4987PTX-MVs) demonstrated a strong anti proliferative activity on CFPAC-1. FTIR analysis of SR4987PTX-MVs showed the presence of an absorption spectrum in the corresponding regions of the PTX marker, absent in MVs from SR4987. Our work is the first demonstration that MSCs are able to package and deliver active drugs through their MVs, suggesting the possibility of using MSCs as a factory to develop drugs with a higher cell-target specificity.
Keywords: Drug delivery; Exosome; Mesenchymal stromal cells; Microvesicles; Paclitaxel.
Copyright © 2014 Elsevier B.V. All rights reserved.
Similar articles
-
Mesenchymal stromal cells primed with paclitaxel provide a new approach for cancer therapy.PLoS One. 2011;6(12):e28321. doi: 10.1371/journal.pone.0028321. Epub 2011 Dec 20. PLoS One. 2011. PMID: 22205945 Free PMC article.
-
Mesenchymal stromal cells primed with Paclitaxel attract and kill leukaemia cells, inhibit angiogenesis and improve survival of leukaemia-bearing mice.Br J Haematol. 2013 Mar;160(6):766-78. doi: 10.1111/bjh.12196. Epub 2013 Jan 7. Br J Haematol. 2013. PMID: 23293837
-
Human skin-derived fibroblasts acquire in vitro anti-tumor potential after priming with Paclitaxel.Anticancer Agents Med Chem. 2013 Mar;13(3):523-30. Anticancer Agents Med Chem. 2013. PMID: 22931415
-
Concise Review: MSC-Derived Exosomes for Cell-Free Therapy.Stem Cells. 2017 Apr;35(4):851-858. doi: 10.1002/stem.2575. Epub 2017 Mar 10. Stem Cells. 2017. PMID: 28294454 Review.
-
Mesenchymal stem cell: an efficient mass producer of exosomes for drug delivery.Adv Drug Deliv Rev. 2013 Mar;65(3):336-41. doi: 10.1016/j.addr.2012.07.001. Epub 2012 Jul 7. Adv Drug Deliv Rev. 2013. PMID: 22780955 Review.
Cited by
-
Extracellular vesicle therapy for traumatic central nervous system disorders.Stem Cell Res Ther. 2022 Sep 2;13(1):442. doi: 10.1186/s13287-022-03106-5. Stem Cell Res Ther. 2022. PMID: 36056445 Free PMC article. Review.
-
Native and engineered extracellular vesicles for wound healing.Front Bioeng Biotechnol. 2022 Dec 9;10:1053217. doi: 10.3389/fbioe.2022.1053217. eCollection 2022. Front Bioeng Biotechnol. 2022. PMID: 36568307 Free PMC article. Review.
-
Engineering Extracellular Vesicles as Nanotherapeutics for Regenerative Medicine.Biomolecules. 2019 Dec 28;10(1):48. doi: 10.3390/biom10010048. Biomolecules. 2019. PMID: 31905611 Free PMC article. Review.
-
Could hypoxia influence basic biological properties and ultrastructural features of adult canine mesenchymal stem /stromal cells?Vet Res Commun. 2018 Dec;42(4):297-308. doi: 10.1007/s11259-018-9738-9. Epub 2018 Sep 20. Vet Res Commun. 2018. PMID: 30238341
-
Therapy resistance mediated by exosomes.Mol Cancer. 2019 Mar 30;18(1):58. doi: 10.1186/s12943-019-0970-x. Mol Cancer. 2019. PMID: 30925921 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources